Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KM1 + Chemotherapy in Recurrent/Refractory Ovarian Cancer
NCT05684731Phase 1Recruiting
- Sponsor
- Tongji Hospital
- Start
- Feb 2023
- Primary completion
- Jun 2025
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of KM1 in ovarian cancer, sponsored by Tongji Hospital. Primary endpoints: Dose-limiting toxicity, Adverse events and serious adverse events and 1 more. Started Feb 2023; status: recruiting.
02
Drugs
KM1
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT05684731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05684731.